Research location

Strasbourg

Alsace, France

Published trials50

Site observations53

Linked trials published50

Page1 / 1

Research activity in Strasbourg

Alsace, France

CureCurrent currently publishes aggregate city-level research activity for this location: 50 trials and 53 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Strasbourg

50 linked trials · page 1 of 1

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)NCT07359846 · 2026-01-20 · 1 site observation

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19 · 1 site observation

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05 · 1 site observation

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesNCT07115745 · 2025-09-04 · 1 site observation

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)NCT06977724 · 2025-08-26 · 1 site observation

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorNCT06472245 · 2024-12-03 · 1 site observation

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation

Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)NCT05092984 · 2022-06-22 · 1 site observation

Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life SettingNCT06639620 · 2024-11-12 · 1 site observation

ACTIVE_NOT_RECRUITING

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)NCT06305754 · 2024-06-11 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)NCT06140836 · 2023-12-21 · 1 site observation

ACTIVE_NOT_RECRUITING

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)NCT05973773 · 2023-12-18 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · 2023-12-06 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of LY8888AX in Participants Using a Connected Insulin Management PlatformNCT05893797 · 2023-10-05 · 1 site observation

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)NCT06036836 · 2023-09-29 · 1 site observation

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308 · 2021-10-04 · 1 site observation

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28 · 1 site observation

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)NCT04725188 · 2021-04-20 · 1 site observation

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)NCT04704219 · 2021-02-23 · 1 site observation

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)NCT04626518 · 2020-12-17 · 1 site observation

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)NCT04191096 · 2020-02-12 · 1 site observation

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)NCT03898180 · 2019-05-06 · 1 site observation

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)NCT03834506 · 2019-05-02 · 1 site observation

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)NCT03834519 · 2019-05-02 · 1 site observation

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisNCT03915964 · 2019-04-25 · 1 site observation

Real-life Effectiveness of Vortioxetine in DepressionNCT03555136 · 2017-11-17 · 1 site observation

ADDIA Chronobiological StudyNCT02973971 · 2016-11-01 · 1 site observation

National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real LifeNCT02925338 · 2016-10-19 · 1 site observation

ADDIA Proof-of-Performance Clinical StudyNCT03030586 · 2016-09-01 · 1 site observation

Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-IvacaftorNCT03512119 · 2016-02-11 · 1 site observation

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyNCT02538666 · 2015-10-13 · 1 site observation

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT02495974 · 2015-09-08 · 1 site observation

Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 DiabetesNCT02411253 · 2015-06-01 · 4 site observations

Surgery of Subclinical Cortisol Secreting Adrenal IncidentalomasNCT02364089 · 2015-04-09 · 1 site observation

Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple SclerosisNCT02904876 · 2015-03-01 · 1 site observation

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyNCT02322281 · 2015-02-01 · 1 site observation

Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma PatientsNCT02212483 · 2014-09-05 · 1 site observation

Validation of a Kinetic Model of ErlotinibNCT02904850 · 2014-06-01 · 1 site observation

Autobiographical Memory Organization in SchizophreniaNCT02570594 · 2014-01-01 · 1 site observation

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerNCT02003924 · 2013-10-31 · 1 site observation

Assessment of Cognitive Function After Surgery in Two Types of Anesthesia in Patients Operated for Breast CancerNCT01880541 · 2010-12-01 · 1 site observation

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate CancerNCT01212991 · 2010-09-16 · 1 site observation

Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's TreatmentNCT01148680 · 2010-06-01 · 1 site observation

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisNCT01064401 · 2010-05-01 · 1 site observation

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).NCT00974974 · 2009-09-01 · 1 site observation

Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in FranceNCT00812357 · 2009-04-01 · 1 site observation

Predisposition and Transition Mechanisms From Arterial Hypertension to Heart FailureNCT02430805 · 2008-11-01 · 1 site observation

Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive PatientsNCT00199979 · 2005-04-01 · 1 site observation

Transpulmonary Gradient After Cardiac Surgery Under Cardiopulmonary BypassNCT01723930 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.